Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial
Purpose/Objective(s): To analyze the long term efficacy and safety of an ultra-hypofractionated (UHF) radiation therapy prostate treatment regimen with HDR brachytherapy boost (BB) and compare it to moderate-hypofractionated regimens (MHF). Materials/Methods: In this single arm, prospective monocent...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Clinical and Translational Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630823000186 |
| _version_ | 1797838582659940352 |
|---|---|
| author | M.M. Beaudry D. Carignan W. Foster M.C. Lavallee S. Aubin F. Lacroix E. Poulin B. Lachance P. Després L. Beaulieu E. Vigneault A.G. Martin |
| author_facet | M.M. Beaudry D. Carignan W. Foster M.C. Lavallee S. Aubin F. Lacroix E. Poulin B. Lachance P. Després L. Beaulieu E. Vigneault A.G. Martin |
| author_sort | M.M. Beaudry |
| collection | DOAJ |
| description | Purpose/Objective(s): To analyze the long term efficacy and safety of an ultra-hypofractionated (UHF) radiation therapy prostate treatment regimen with HDR brachytherapy boost (BB) and compare it to moderate-hypofractionated regimens (MHF). Materials/Methods: In this single arm, prospective monocentric study, 28 patients with intermediate risk prostate cancer were recruited in an experimental treatment arm of 25 Gy in 5 fractions plus a 15 Gy HDR BB. They were then compared to two historical control groups, treated with either 36 Gy in 12 fractions or 37.5 Gy in 15 fractions with a similar HDR BB. The control groups included 151 and 311 patients respectively. Patient outcomes were reported using the International Prostate Symptom Score (IPSS) and Expanded Prostate Index Composite (EPIC-26) questionnaires at baseline and at each follow-up visit. Results: Median follow-up for the experimental arm was 48.5 months compared to 47 months and 60 months compared to the 36/12 and 37,5/15 groups respectively. The IPSS and EPIC scores did not demonstrate any significant differences in the gastrointestinal or genitourinary domains between the three groups over time. No biochemical recurrence occurred in the UHF arm as defined by the Phoenix criterion. Conclusion: The UHF treatment scheme with HDR BB seems equivalent to standard treatment arms in terms of toxicities and local control. Randomized control trials with larger cohorts are ongoing and needed to further confirm our findings. |
| first_indexed | 2024-04-09T15:43:11Z |
| format | Article |
| id | doaj.art-83e258f8f982461c93f83adddd52d409 |
| institution | Directory Open Access Journal |
| issn | 2405-6308 |
| language | English |
| last_indexed | 2024-04-09T15:43:11Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical and Translational Radiation Oncology |
| spelling | doaj.art-83e258f8f982461c93f83adddd52d4092023-04-27T06:06:20ZengElsevierClinical and Translational Radiation Oncology2405-63082023-05-0140100593Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trialM.M. Beaudry0D. Carignan1W. Foster2M.C. Lavallee3S. Aubin4F. Lacroix5E. Poulin6B. Lachance7P. Després8L. Beaulieu9E. Vigneault10A.G. Martin11CHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, Canada; Corresponding author.Centre de recherche sur le cancer, Université Laval, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, Canada; Centre de recherche sur le cancer, Université Laval, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, Canada; Centre de recherche sur le cancer, Université Laval, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, Canada; Centre de recherche sur le cancer, Université Laval, Québec, QC, CanadaCHU de Québec-Université Laval, Service de radio-oncologie, Québec, QC, Canada; Centre de recherche sur le cancer, Université Laval, Québec, QC, CanadaPurpose/Objective(s): To analyze the long term efficacy and safety of an ultra-hypofractionated (UHF) radiation therapy prostate treatment regimen with HDR brachytherapy boost (BB) and compare it to moderate-hypofractionated regimens (MHF). Materials/Methods: In this single arm, prospective monocentric study, 28 patients with intermediate risk prostate cancer were recruited in an experimental treatment arm of 25 Gy in 5 fractions plus a 15 Gy HDR BB. They were then compared to two historical control groups, treated with either 36 Gy in 12 fractions or 37.5 Gy in 15 fractions with a similar HDR BB. The control groups included 151 and 311 patients respectively. Patient outcomes were reported using the International Prostate Symptom Score (IPSS) and Expanded Prostate Index Composite (EPIC-26) questionnaires at baseline and at each follow-up visit. Results: Median follow-up for the experimental arm was 48.5 months compared to 47 months and 60 months compared to the 36/12 and 37,5/15 groups respectively. The IPSS and EPIC scores did not demonstrate any significant differences in the gastrointestinal or genitourinary domains between the three groups over time. No biochemical recurrence occurred in the UHF arm as defined by the Phoenix criterion. Conclusion: The UHF treatment scheme with HDR BB seems equivalent to standard treatment arms in terms of toxicities and local control. Randomized control trials with larger cohorts are ongoing and needed to further confirm our findings.http://www.sciencedirect.com/science/article/pii/S2405630823000186Prostate cancerBrachytherapyUltrahypofractionationToxicitiesHypofractionation |
| spellingShingle | M.M. Beaudry D. Carignan W. Foster M.C. Lavallee S. Aubin F. Lacroix E. Poulin B. Lachance P. Després L. Beaulieu E. Vigneault A.G. Martin Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial Clinical and Translational Radiation Oncology Prostate cancer Brachytherapy Ultrahypofractionation Toxicities Hypofractionation |
| title | Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial |
| title_full | Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial |
| title_fullStr | Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial |
| title_full_unstemmed | Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial |
| title_short | Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial |
| title_sort | comparison of four year toxicities and local control of ultra hypofractionated vs moderate hypofractionated image guided prostate radiation with hdr brachytherapy boost a phase i ii single institution trial |
| topic | Prostate cancer Brachytherapy Ultrahypofractionation Toxicities Hypofractionation |
| url | http://www.sciencedirect.com/science/article/pii/S2405630823000186 |
| work_keys_str_mv | AT mmbeaudry comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT dcarignan comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT wfoster comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT mclavallee comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT saubin comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT flacroix comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT epoulin comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT blachance comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT pdespres comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT lbeaulieu comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT evigneault comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial AT agmartin comparisonoffouryeartoxicitiesandlocalcontrolofultrahypofractionatedvsmoderatehypofractionatedimageguidedprostateradiationwithhdrbrachytherapyboostaphaseiiisingleinstitutiontrial |